Original article by Jessica Gardner
The Australian Financial Review – Page: 11 & 17 : 18-Mar-15

Sirtex Medical’s shares closed 55 per cent lower at $A17.53 on 17 March 2015, after the group released the results of a seven-year clinical trial of its SIR-Spheres treatment for liver cancer. The trial found that the treatment does not offer much improvement compared with traditional treatments such as chemotherapy. However, Sirtex intends to make more extensive data on the clinical trial available in May

CORPORATES
SIRTEX MEDICAL LIMITED – ASX SRX, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, MESOBLAST LIMITED – ASX MSB, CSL LIMITED – ASX CSL, ONCOSIL MEDICAL LIMITED – ASX OSL, MORGANS FINANCIAL LIMITED, BLOOMFIELD COLLIERIES, UBS HOLDINGS PTY LTD, WILSON HTM INVESTMENT GROUP LIMITED – ASX WIG, AUSTRALIAN ETHICAL INVESTMENT LIMITED – ASX AEF